HC Wainwright reiterated their buy rating on shares of BELLUS Health (TSE:BLU) in a research note issued to investors on Friday, Zacks.com reports.
Shares of BLU stock opened at C$13.61 on Friday. The firm has a 50-day moving average price of C$14.34 and a 200 day moving average price of C$12.42. BELLUS Health has a twelve month low of C$7.37 and a twelve month high of C$16.68. The company has a market capitalization of $855.52 million and a price-to-earnings ratio of -22.24. The company has a current ratio of 15.47, a quick ratio of 15.01 and a debt-to-equity ratio of 0.12.
BELLUS Health (TSE:BLU) last announced its earnings results on Thursday, May 14th. The company reported C($0.24) earnings per share for the quarter, beating the consensus estimate of C($0.25) by C$0.01. The firm had revenue of C$0.01 million during the quarter, compared to analyst estimates of C$0.01 million.
About BELLUS Health
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.
Further Reading: Discover Your Risk Tolerance
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.